Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,709 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.
Nishigaya Y, Takase S, Sumiya T, Kikuzato K, Sato T, Niwa H, Sato S, Nakata A, Sonoda T, Hashimoto N, Namie R, Honma T, Umehara T, Shirouzu M, Koyama H, Yoshida M, Ito A, Shirai F. Nishigaya Y, et al. Among authors: sato s, sato t. J Med Chem. 2023 Mar 23;66(6):4059-4085. doi: 10.1021/acs.jmedchem.2c02059. Epub 2023 Mar 7. J Med Chem. 2023. PMID: 36882960
Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.
Koda Y, Sato S, Yamamoto H, Niwa H, Watanabe H, Watanabe C, Sato T, Nakamura K, Tanaka A, Shirouzu M, Honma T, Fukami T, Koyama H, Umehara T. Koda Y, et al. Among authors: sato s, sato t. ACS Med Chem Lett. 2022 Apr 29;13(5):848-854. doi: 10.1021/acsmedchemlett.2c00120. eCollection 2022 May 12. ACS Med Chem Lett. 2022. PMID: 35586426 Free PMC article.
Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
Sato T, Watanabe H, Tsuganezawa K, Yuki H, Mikuni J, Yoshikawa S, Kukimoto-Niino M, Fujimoto T, Terazawa Y, Wakiyama M, Kojima H, Okabe T, Nagano T, Shirouzu M, Yokoyama S, Tanaka A, Honma T. Sato T, et al. Bioorg Med Chem. 2012 Jun 15;20(12):3756-67. doi: 10.1016/j.bmc.2012.04.042. Epub 2012 Apr 27. Bioorg Med Chem. 2012. PMID: 22607878
Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto H, Sakai N, Ohte S, Sato T, Sekimata K, Matsumoto T, Nakamura K, Watanabe H, Mishima-Tsumagari C, Tanaka A, Hashizume Y, Honma T, Katagiri T, Miyazono K, Tomoda H, Shirouzu M, Koyama H. Yamamoto H, et al. Among authors: sato t. Bioorg Med Chem Lett. 2021 Apr 15;38:127858. doi: 10.1016/j.bmcl.2021.127858. Epub 2021 Feb 18. Bioorg Med Chem Lett. 2021. PMID: 33609658
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches.
Sato T, Sekimata K, Sakai N, Watanabe H, Mishima-Tsumagari C, Taguri T, Matsumoto T, Fujii Y, Handa N, Tanaka A, Shirouzu M, Yokoyama S, Hashizume Y, Miyazono K, Koyama H, Honma T. Sato T, et al. ACS Omega. 2020 May 12;5(20):11411-11423. doi: 10.1021/acsomega.9b04245. eCollection 2020 May 26. ACS Omega. 2020. PMID: 32478230 Free PMC article.
Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K, Sato T, Sakai N, Watanabe H, Mishima-Tsumagari C, Taguri T, Matsumoto T, Fujii Y, Handa N, Honma T, Tanaka A, Shirouzu M, Yokoyama S, Miyazono K, Hashizume Y, Koyama H. Sekimata K, et al. Among authors: sato t. Chem Pharm Bull (Tokyo). 2019;67(3):224-235. doi: 10.1248/cpb.c18-00598. Chem Pharm Bull (Tokyo). 2019. PMID: 30828000 Free article.
16,709 results
You have reached the last available page of results. Please see the User Guide for more information.